{
  "image_filename": "table_p13_det_12_007.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/table_p13_det_12_007.png",
  "image_type": "Table",
  "page_number": 13,
  "block_id": "det_12_007",
  "claim_id": "claim_002",
  "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
  "supports_claim": false,
  "explanation": "Table listing various quadrivalent influenza vaccines by brand name and manufacturer alongside their dose volumes and hemagglutinin antigen content (e.g., Flucelvax Quadrivalent (Seqirus) 0.5 mL (15 \u00b5g), Fluarix Quadrivalent (GlaxoSmithKline) 0.5 mL (15 \u00b5g), Afluria Quadrivalent (Seqirus) 0.25 mL (7.5 \u00b5g), FluLaval Quadrivalent (GlaxoSmithKline) 0.5 mL (15 \u00b5g), Fluzone Quadrivalent (Sanofi Pasteur) 0.5 mL (15 \u00b5g)). does not support the claim because the table only provides vaccine names, manufacturers, and dosage information, with no data or statements about mutations arising during production or impacts on effectiveness.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table listing various quadrivalent influenza vaccines by brand name and manufacturer alongside their dose volumes and hemagglutinin antigen content (e.g., Flucelvax Quadrivalent (Seqirus) 0.5 mL (15 \u00b5g), Fluarix Quadrivalent (GlaxoSmithKline) 0.5 mL (15 \u00b5g), Afluria Quadrivalent (Seqirus) 0.25 mL (7.5 \u00b5g), FluLaval Quadrivalent (GlaxoSmithKline) 0.5 mL (15 \u00b5g), Fluzone Quadrivalent (Sanofi Pasteur) 0.5 mL (15 \u00b5g)).",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only provides vaccine names, manufacturers, and dosage information, with no data or statements about mutations arising during production or impacts on effectiveness.",
    "confidence_notes": null
  }
}